Table 2. Subgroup analysis based on FMT use method in short-term outcomes.
| Category | Subgroup | MD | 95%Cl | I2 |
|---|---|---|---|---|
| Weight | Capsules | 3.85 | -5.37, 13.07 | 0% |
| Nasoduodenal tube | 1.13 | -15.21, 17.46 | 50% | |
| BMI | Capsules | 0.18 | -2.76, 3.11 | 0% |
| Nasoduodenal tube | -0.29 | -1.53, 0.94 | 0% | |
| Fasting glucose | Capsules | -0.10 | -0.28, 0.07 | 0% |
| Nasoduodenal tube | -0.17 | -0.42, 0.08 | 57% | |
| HbA1C | Capsules | -0.11 | -0.39, 0.17 | 0% |
| Nasoduodenal tube | -0.83 | -1.32, -0.34 | 50% | |
| HOMA-IR | Capsules | 0.02 | -0.65, 0.70 | 0% |
| Nasoduodenal tube | 0.6 | -1.39, 2.59 | ------ | |
| Insulin | Capsules | -14.24 | -55.46, 26.98 | 0% |
| Nasoduodenal tube | -25.90 | -39.40, -12.40 | ------ | |
| Cholesterol | Capsules | 0.10 | -0.16, 0.36 | 0% |
| Nasoduodenal tube | 0.01 | -0.15, 0.17 | 30% | |
| LDLc | Capsules | 0.13 | -0.10, 0.35 | 19% |
| Nasoduodenal tube | 0.13 | -0.09, 0.34 | 0% | |
| HDLc | Capsules | 0.04 | -0.05, 0.12 | 0% |
| Nasoduodenal tube | 0.08 | 0.03, 0.13 | 56% | |
| Triglycerides | Capsules | -0.03 | -0.19, 0.14 | 0% |
| Nasoduodenal tube | -0.03 | -0.16, 0.10 | 56% |
BMI: Body mass index; HbA1c: Hemoglobin A1c (glycated hemoglobin); HOMA-IR: Homeostatic model assessment of insulin resistance; LDL: Low density lipoprotein; HDL: High density lipoprotein